Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, VivoSim Labs's Enterprise Value is €-2.55 Mil.
VivoSim Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €-9.32 Mil. Therefore, VivoSim Labs's EV-to-OCF for today is 0.27.
The historical rank and industry rank for VivoSim Labs's EV-to-OCF or its related term are showing as below:
FRA:4OR'
s EV-to-OCF Range Over the Past 10 Years
Min: -11.66 Med: -0.78 Max: 1.31
Current: 0.32
During the past 13 years, the highest EV-to-OCF of VivoSim Labs was 1.31. The lowest was -11.66. And the median was -0.78.
FRA:4OR's EV-to-OCF is ranked worse than 74.59% of 1409
companies
in the Biotechnology industry
Industry Median: -3.48
vs FRA:4OR: 0.32
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
VivoSim Labs's PE Ratio (TTM) for today is calculated as:
VivoSim Labs's share price for today is €3.492.
VivoSim Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.615.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
VivoSim Labs EV-to-OCF Related Terms
VivoSim Labs EV-to-OCF Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs MTNB, HEPA, CLSDQ: EV-to-OCF Comparison
For the Biotechnology subindustry, VivoSim Labs's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's EV-to-OCF falls into.
VivoSim Labs's current Enterprise Value is €-2.55 Mil.
VivoSim Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a EV-to-OCF of 0.27 as of Aug. 08, 2026. According to the industry distribution chart, VivoSim Labs ranks #1051 out of 1409 companies in the Biotechnology industry, placing it in the top 74.6%.
Is VivoSim Labs' EV-to-OCF too high?
VivoSim Labs' current EV-to-OCF is 0.27. Based on the distribution chart, VivoSim Labs ranks #1051 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' EV-to-OCF compare to MTNB and HEPA?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #1051 out of 1409 companies for EV-to-OCF. This places VivoSim Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. VivoSim Labs's current EV-to-OCF is 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current EV-to-OCF of 0.27. The stock's GF Value™ is €22.21, compared to a current price of €3.49 — trading 84.3% below its estimated fair value. The current EV-to-OCF is 0.27. VivoSim Labs' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current EV-to-OCF is 0.27 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 84.3% below its estimated GF Value™ of €22.21.
Key valuation signals for FRA:4OR:
EV-to-OCF: 0.27
GF Value™: €22.21 vs. price of €3.49 (84.3% below fair value)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
33GF Score
Get the complete analysis for FRA:4OR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
